Ginkgo Bioworks Q3 revenue drops, net loss widens, reaffirms 2025 revenue outlook

Ginkgo Bioworks Holdings

06/11/2025 21:49

Overview

Ginkgo Q3 2025 revenue falls 56% yr/yr

Company reports Q3 GAAP net loss of $81 mln, increased from prior year

Adjusted EBITDA for Q3 2025 declines to $(56) mln from $(20) mln last year

Outlook

Ginkgo reaffirms 2025 total revenue of $167-$187 mln

Ginkgo expects 2025 Cell Engineering revenue of $117-$137 mln

Ginkgo anticipates 2025 Biosecurity revenue of at least $40 mln

Result Drivers

REVENUE DECLINE - Q3 revenue decreased 56% yr/yr, impacted by prior year's non-cash revenue from a terminated customer agreement

AI TECHNOLOGY - Co highlights AI-enabled cloud lab technology as a driver for U.S. scientific innovation

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$80.76 mln
Q3 Operating Expenses
$128.85 mln
Q3 Operating Income
-$90.02 mln
Q3 Pretax Profit
-$80.75 mln


Analyst Coverage

The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy", no "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $9.00, about 28.8% below its November 5 closing price of $11.59

Press Release: ID:nPn6HCG3Ha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)